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Condensation 
The presence of elevated monomeric prolactin concentrations indicates the requirement for further 
examinations and treatment with dopamine receptor agonists in patients with macroprolactinemia. 
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Abstract  
Macroprolactin is an antigen-antibody complex of a higher prolactin (PRL) molecular mass 
(big-big, MW > 150 kDa), consisting of monomeric PRL and immunoglobulin G isotype. The term 
macroprolactinemia is suspected for cases when the concentration of macroprolactin exceeds 60% 
of the total serum PRL concentration determined by the polyethylene-glycol precipitation method. 
The gold standard of the diagnosis of macroprolactinemia is gel filtration chromatography. The 
prevalence of macroprolactinemia in hyperprolactinemic populations varies between 15 and 35%. 
Although the pathogenesis of these antibodies is not clear, it is possible that some changes in the 
pituitary PRL molecule represent an increased antigenicity to the immune system leading to the 
production of anti-PRL antibodies. A mild hyperprolactinemia usually occurs because 
macroprolactin is not readily cleared from circulation due to its higher molecular weight. Moreover, 
the hypothalamic negative feedback mechanism by autoantibody-bound PRL is inactive because 
macroprolactin cannot access to the hypothalamus and therefore results in hyperprolactinemia. 
Reduced in vivo bioactivity of macroprolactin may be the reason for the lack of hyperprolactinemic 
symptoms. It also seems that anti-PRL autoantibodies may compete with the PRL molecule for 
receptor-binding thus resulting in low bioactivity. Additionally, the large molecular size of 
macroprolactin confined in the intravascular compartment prevents its passage through the capillary 
endothelium to the target cell, which may be the reason for the absence of the symptoms. According 
to current concepts macroprolactinemia is considered a benign clinical condition in patients with 
with normal concentrations of bioactive monomeric PRL and with a lack or low incidence of 
hyperprolactinemic symptoms and negative pituitary imaging. In such cases, with resistance to 
antiprolactinemic drugs, no pharmacological treatment, diagnostic investigations or prolonged 
follow-up are required. However,  macroprolactinemia may also occur in patients with any of the 
conventional symptoms of hyperprolactinemia which could not be differentiated from those with 
true hyperprolactinemia. These symptoms are mostly attributed to the excess of monomeric PRL 
and its presence is of overridden concern, and the diagnosis of macroprolactinemia is misleading 
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and inappropriate. A multitude of causes, like physiological, pharmacological and pathological, 
including stress, prolactinomas, hypothyroidism, renal and hepatic failure, intercostal nerve 
stimulation,  and polycystic ovary disease can contribute to the rise in the levels of monomeric PRL. 
It is important for patients with elevated monomeric PRL to undergo routine evaluation of 
hyperprolactinemia identifying the exact pathologic state and introducing adequate treatment 
regardless of the presence of macroprolactin. In addition,  macroprolactinemia may rarely occur due 
to macroprolactin associated with pituitary adenomas, with biological activity of macroprolactin 
comparable with that of monomeric PRL. In these cases when excess of macroprolactin occurs with 
clinical manifestations of hyperprolactinemia, macroprolactinemia should be regarded a 
pathological biochemical variant of hyperprolactinemia. An individualized approach to the 
management of such patients with macroprolactinemia may be necessary and pituitary imaging, 
dopamine treatment, and prolonged follow-up should be applied.                                                                                                    
Keywords: Macroprolactin, Hyperprolactinemia, Diagnosis, Treatment 
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1. Introduction 
Prolactin (PRL) is a single globular polypeptide hormone synthesized and secreted by 
pituitary lactotroph cells. Heterogeneity in its molecular size has been described in the serum and 
three major variants can be found including monomeric PRL, dimeric and polymeric isoforms. PRL 
is synthesized as a prehormone (MW 26 kDa) and after cleavage the resulting hormone is a 
monomeric isoform of PRL (little PRL, MW 23 kDa). This monomeric PRL is the major form in 
the blood of subjects with normoprolactinemia and true hyperprolactinemia, accounting for 80-95% 
of the total PRL. It is known to be both biologically and immunologically active in vivo with a half-
life of 26-47 min. The other forms mainly include the dimeric (big PRL, MW 48-56 kDa) and the 
polymeric isoform (big-big PRL, MW > 150 Da) or macroprolactin. In normal sera the dimeric 
isoform makes up < 10% of the PRL present and the polymeric isoform accounts for a small (less 
than 1%) but variable percentage of the total PRL and these two forms are known to have lower 
biological activity. The term macroprolactinemia is characterized by predominant presence of 
macroprolactin and it is suspected mainly in asymptomatic subjects or those without the typical 
hyperprolactinemia-related symptoms. In addition to prolactinomas and neuroleptics/antipsychotic 
agents, macroprolactinemia is one the three most common causes of hyperproplactinemia [1]. The 
nature of macroprolactin is heterogenous and it is mainly identified as an antigen-antibody complex 
of high stability consisting primarily of monomeric PRL and immunoglobulin (Ig) G isotype. 
However, non-IgG-bound forms of macroprolactin (complexes with IgA or IgM; highly 
glycosylated monomeric PRL, covalent or noncovalent  aggregates of monomeric PRL) are rarely 
detected, mainly in sera with marginally elevated levels. In spite of low in vitro bioactivity, the 
complex apparently lacks in vivo bioactivity although macroprolactin retains its immunoreactivity 
properties. Owing to its high molecular weight, macroprolactin is confined to the vascular system 
which may reduce its access to the PRL receptors of target organs in the periphery as well as 
centrally and it is thus bio-unavailable resulting in asymptomatic hyperprolactinemia [2,3]. 
Therefore, typical symptoms of hyperprolactinemia (oligomenorrhea, amenorrhea, galactorrhea, 
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infertility etc.) and abnormal imaging changes in the pituitary gland are not common in patients in 
whom macroprolactin is the predominant form of PRL. These IgG type autoantibodies have a low 
affinity and high capacity, and long-term follow-up revealed that macroprolactinaemia might be a 
long-lasting condition [3,4]. In patients with macroprolactinemia and normal concentrations of 
monomeric PRL there was a low incidence of hyperprolactinemia-related symptoms during 
prolonged follow-up. It has been suggested that macroprolactinemia should be considered a benign 
variant with mildly elevated PRL levels and a cause of evident resistance to antiprolactinemic 
drugs. Moreover, such patients can be reassured because no pituitary imaging investigations, 
dopamine agonist treatments, and prolonged follow-up would be necessary [5]. In addition, routine 
screening of all hyperprolactinemic sera for macroprolactin may be recommended because reduced 
use of imaging and dopamine agonist treatment in macroprolactinemic patients would be cost-
effective resulting in net cost savings [6]. 
However, not all patients with macroprolactinemia lack clinical symptoms because there are 
a number of reports regarding the overlapping of the main hyperprolactinemic symptoms due to the 
rise in the levels of monomeric PRL in subjects with true hyperprolactinemia and those with 
macroprolactinemia [7-11]. Moreover, no laboratory features in addition to clinical features could 
reliably differentiate macroprolactinemic patients from those with monomeric hyperprolactinemia 
[8]. Comparison of multiple methods for the identification of hyperprolactinemia in the presence of 
macroprolactin revealed no difference in the prevalence of abnormal menses, galactorrhea, or 
abnormal pituitary imaging between the patients with and without macroprolactin [9]. Although 
oligomenorrhea and galactorrhea occurred more frequently in patients with true hyperprolactinemia, 
they also occurred in 57% and 29%, respectively, of macroprolactinemic patients and these 
differences were not sufficient to distinguish between the two groups on the basis of clinical 
symptoms alone. Moreover, hyperprolactinemia due to macroprolactin led to diagnostic confusion, 
unnecessary investigations, and unsuitable treatment before the introduction of macroprolactin 
screening by application of a reference interval to polyethylene glycol (PEG)-treated 
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hyperprolactinemic sera [10]. Therefore, it is important that laboratories introduce screening 
programmes to examine samples with elevated total immunoreactive PRL for the presence of 
macroprolactin and to determine the monomeric PRL component which is responsible for 
bioactivity in vivo [11]. In a recent study a few cases of macroprolactinemia of pituitary origin 
associated with prolactinoma experienced similar clinical manifestations comparable with that of 
monomeric hyperprolactinemia, and their disappearance after treatment with dopamine agonists 
suggesting bioactivity of macroprolactin. Therefore, in spite of the fact that macroprolactinemia had 
been considered a benign condition, pituitary imaging and conservative treatment with dopamine 
agonists and prolonged follow-up should be applied in these rare cases as well as in 
macroprolactinemic patients with elevated monomeric hyperprolactinemia [12]. In this review we 
report various clinical features of macroprolactinemia explained through pathophysiologic 
mechanisms suggesting different approaches which would contribute to the improvement of proper 
identification and adequate management of such patients.   
2. Prevalence 
The proportion of macroprolactinemia in the general population has previously been 
reported at 0.2% in women and 0.02% in men [13]. However,  macroprolactinemia may be more 
common, with a recently reported prevalence of 3.7% and no difference in prevalence between 
genders [14]. Because the reported proportion of macroprolactinemia in hyperprolactinemic 
populations is much higher in most studies and varies between 15 and 35% (mean prevalence 25%), 
macroprolactinemia is therefore considered a common finding  in endocrinological practice [3, 8, 
12, 13]. One study reported a prevalence of 46%, but it is likely that this particular incidence 
reflected selection bias because of the specialized nature of the study center, which received 
samples sent from other laboratories when the possible diagnosis of macroprolactinemia was raised 
[15]. 
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3. Clinical features 
 The earliest reports of macroprolactinemia were isolated cases in patients being investigated 
for nonreproductive endocrine problems or healthy research volunteers who had no symptoms of 
hyperprolactinemia, but normal menstruation and maintained fertility. Analysis of circulating PRL 
by column chromatography revealed that between 85-90% of serum PRL was big-big PRL  with 
normal levels of monomeric PRL. The reduced biological activity of macroprolactin  has been 
suggested as the reason for the lack of symptoms which might be the result of the big-big PRL 
complex preventing passage through the capillary endothelium to the target cell [16-18]. The new 
term macroprolactinemia was used for the first time in 1985 to denote a nonprogressive state and a 
novel cause of hyperprolactinemia [18].  
However, further, more comprehensive serial investigations of patients with 
macroprolactinemia reported a mild symptomatology with a lower incidence of clinical symptoms 
and abnormal imaging findings in the pituitarry gland than in patients with true hyperprolactinemia 
[3, 5, 10, 15, 19-22]. During prolonged follow-up of a cohort of 51 patients with 
macroprolactinemia headache had been experienced in 12 patients (24%),  oligomenorrhea in five 
(10%) and galactorrhea was present in only two cases  (4%) with no symptomatic progression in 
any of the  patients [5]. Among 113 patients with hyperprolactinemia clinical symptoms were more 
likely to occur in individuals with true hyperprolactinemia than in patients with macroprolactinemia  
(90% vs.54%) [15]. Out of 55 patients with macroprolactinemia none of the patients had sustained 
amenorrhea,  one had galactorrhea and eight have had oligomenorrhea at age bellow 40 years [19]. 
Menstrual abnormalities and galactorrhea occurred less frequently in 106 patients with 
macroprolactinemia compared with patients with true hyperprolactinemia  [20]. The prevalence of 
oligomenorrhea and galactorrhea was significantly higher in 164 patients with true 
hyperprolactinemia than in 21 patients with macroprolactinemia (46 vs. 14 % and 30 vs. 5 %, 
respectively) [21]. Among 337 patients with hyperprolactinemia more patients in the 
macroprolactinemic group were asymptomatic compared to the monoprolactinemic group (30.2 vs. 
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12.0%). Compared to the macroprolactinemic group, the monoprolactinemic group had a higher 
frequency of galactorrhea (39.2 vs. 57.1%) and abnormal magnetic resonance imaging findings 
(65.3 vs. 81.1%). It was concluded that macroprolactinemia should be considered a pathological 
biochemical variant of hyperprolactinemia that may present with any of the conventional symptoms 
and radiological findings generally associated with elevated PRL levels [22]. 
Morever, in other investigations symptoms related to PRL excess were reported more 
frequently in subjects with macroprolactinemia. There was no difference in the frequency of clinical 
features between macroprolactinemic and true hyperprolactinemic patients. [7-9, 23].  In addition to 
overlapping in hyperprolactinemia-related symptoms between the groups there were no significant 
differences in serum gonadotrophins, estradiol or testosterone levels. Nevertheless, the patients with 
macroprolactinemia had a lower infertility rate (6.7% vs. 32.7%) and a greater percentage of normal 
magnetic resonance imaging of the pituitary gland (73.3% vs. 34.5%) than those with monomeric 
hyperprolactinemia. Therefore, it was suggested that routine laboratory screening with PEG for all 
hyperprolactinemic sera might prevent the unnecessary use of radiological techniques and medical 
treatment for hyperprolactinemic patients [23]. 
 
4. Diagnosis 
 For an accurate diagnosis of macroprolactinemia laboratory and radiological techniques are 
essential in the evaluation of hyperprolactinemia.   
The gel filtration chromatography (GFC) is known as the gold standard or the reference 
assay for the separation of macroprolactin from mono- and dimeric PRL. Although the technique of 
GFC is accurate and reproducible, it is an expensive, time-consuming and labor intensive method 
which precludes its widespread use and prompted more diagnostic laboratories to develop 
nonchromatographic screening methods [20]. 
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 Separation of macroprolactin by immunoadsorption with Protein A (PA) and Protein G 
(PG), immobilized on Sepharose, is based on high affinity of the PA and PG for human IgG, which 
is a primary antibody to PRL in serum. Although this method exhibits acceptable precision and the 
recovery of standard preparation is satisfactory, pretreatment of sera with PA and PG may lead to a 
significant overestimation of monomeric PRL concentrations [24]. 
 Separation of macroprolactin by means of ultrafiltration is based on the passage of PRL 
through the separating membrane which selectively retains particles according to their molecular 
size, net charge and three-dimensional structure. Although ultrafiltration represents a practical and 
precise alternative to GFC for estimating the macroprolactin in serum, the PRL concentrations 
recorded after ultrafiltration, compared with those after GFC, may vary considerably from sample 
to sample [24, 25]. 
A number of studies have shown that PEG induced precipitation of macroprolactin in serum 
sample represents a simple, inexpensive, accessible, rapid and reproducible screening technique for 
hyperprolactinemic sera [19, 26, 27]. The method is based on different precipitation of proteins 
according to their molecular weight and solubility in different concentrations of PEG solution. To 
determine free PRL concentrations, a concentration of 25% PEG is added to the same volume of 
serum which precipitates out high-molecular weight constituents including immunoglobulins. It is 
not necessary to incubate the PEG-treated sample but the usage of cold PEG and the vortex mixing 
are important. Free PRL is defined as the  PRL  concentration in the supernatant  after  PEG  
precipitation, and total PRL is defined as the PRL concentration in the water-treated sample. The 
PEG–precipitable PRL (%) represents the amount of macroprolactin calculated as follows: (total 
PRL−free PRL)/total PRL×100. It has been generally accepted that a PEG-precipitation ratio 
greater than 60% (recovery less than 40%) is the cut-off value for the diagnosis of 
macroprolactinemia. This is because there is no a clear-cut value of “substantial increase”, but 
conventionally a diagnosis of macroprolactinemia is made when more than 30–60% of PRL is in 
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the macroprolactin form of GFC  [6, 9, 24, 26-28]. Precipitation with PEG is a widely used 
screening test for macroprolactin and is easily performed in clinical laboratories. However, PEG 
also induces a partial precipitation of monomeric PRL (up to 25%) so reliance on the relative 
percentage of recovery lacks specificity which may lead to an underestimated evaluation and 
misinterpretation of actual PRL levels [24]. This is especially important in cases when an excessive 
macroprolactin occurs in patient’s serum simultaneously with supraphysiological concentrations of 
monomeric PRL  [9, 26, 29].  Furthermore, it has been reported that the presence of PEG in the 
sample can interfere with some PRL immunoassay procedures [30]. To avoid such problems, it has 
been recommended that each laboratory, undertaking macroprolactin screening, must establish 
method-specific reference intervals derived by use of PEG-treated sera from healthy individuals [9, 
26, 29]. In routine laboratory diagnostics the post-PEG modified reference range is the best means 
to accurately identify patients with true hyperprolactinemia [9]. 
Data regarding radiological evaluation of the pituitary gland by using computerized axial 
tomography and magnetic resonance imaging are usually limited because the presence of 
macroprolactin is suspected mainly in subjects with mild hyperprolactinemia and negative pituitary 
imaging. The prevalence of macroprolactinemia among newly diagnosed prolactinoma patients is 
similar compared with the control group of healthy subjects (3.5 vs. 3.7%), and may be explained 
by the coexistence of a pituitary adenoma and macroprolactinemia  or macroprolactin production by 
the pituitary tumour itself [12]. 
 
5. Pathophysiology  
In the majority of patients the etiology of macroprolactinemia is thought to be an extrapituitary 
postsecretory phenomenon of anti-PRL autoantibodies, confined to the vascular system with most 
often lack of bioactivity in vivo and normal concentrations of monomeric PRL with the 
consequence being the absence of symptoms. This absence of macroprolactin in extravascular 
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spaces and the pituitary gland might be explained by the high molecular weight of the 
macroprolactin molecules, which cannot cross the endothelium and thus remain in the intravascular 
compartment preventing its access to PRL receptors at all. Because the clearance of macroprolactin 
by the kidneys is delayed macroprolactinemia may be a  condition of prolonged duration. The 
clearance of PRL is slower in the presence of anti-PRL antibodies, suggesting that the antibody-
bound PRL is big enough to be confined to vascular spaces, which also precludes filtration of the 
bound PRL filtration from the glomeruli. Therefore macroprolactinemia develops due to the 
delayed clearance of PRL rather than increased production. These PRL autoantibodies are stable 
with time and long-term follow-up (>10 years) revealed that macroprolactinemia might be a long-
lasting condition in humans [3,4,19,28]. The second reason for the asymptomatic presentation of 
macroprolactinemia includes binding of anti-PRL autoantibodies to their binding sites (epitopes) in 
both N- and C-terminal residues of the PRL molecule which are located near the binding site 1 to 
PRL receptors. It seems that anti-PRL autoantibodies may compete with the PRL molecule for 
binding to its receptors, thus leading to low bioactivity in vivo [31]. Comparing two different 
bioassays it was found that the biological activity of human macroprolactin was considerably lower 
toward the homologous receptor-mediated Ba/F-LLP assay than in the commonly used 
heterologous rat Nb2 cell assay. Therefore, the usage of  the homologous Ba/F-LLP assay correlates 
well with the assumption that the bioactivity of macroprolactin is very low in vivo and the activity 
displayed by macroprolactin toward the rat receptor may be inappropriate [32]. 
Although the pathogenesis and the source of these antibodies is not yet absolutely clear it is 
possible that some autoimmune disorders like thyroid disorders and systemic lupus erythematodes 
may be accompanied with macroprolactinemia [33]. However, other studies examining a large 
number of patients revealed no specific association between macroprolactinemia and systemic 
autoimmune disorders [20,34]. It was found that macroprolactinaemic sera did not yield evidence of 
an increase in markers of autoimmunity when compared with hyperprolactinaemic or normal sera 
[34]. It is proposed that genetic susceptibility and environmental factors are the mechanisms 
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involved in the development of anti-PRL autoantibodies which may alter the immune response in 
hosts as postulated in other autoimmune disorders [35]. On the other hand, pituitary PRL with some 
changes in its molecule represents an increased antigenicity to the immune system. It was found that 
phosphorylated forms of PRL were intolerant to the immune system and leakage of such forms 
upon hypophysitis or lack of dephosphorylation may cause an autoimmune response leading to the 
production of anti-PRL antibodies. The finding that IgG4 was a predominant subtype of PRL 
antibodies supports the possibility that it may be be produced by chronic antigen stimulation [36].  
It has been suggested that anti-PRL autoantibody is a cause of hyperprolactinemia because a 
significant positive correlation may be found between anti-PRL autoantibody titers and serum PRL 
concentrations. It seems that the hypothalamic negative feedback mechanism by autoantibody-
bound PRL does not work because the complex cannot access to the hypothalamus due its size and 
therefore results in mild hyperprolactinemia. However, when serum free PRL concentrations exceed 
normal PRL concentrations, negative feedback mechanisms begin operating to normalize free PRL 
levels which are usually in sera from most macroprolactinemic patients within normal range [14, 
37]. Therefore the biochemical findings of serum estradiol and luteinizing hormone (LH) may be  
significantly higher in individuals with macroprolactinemia compared with those with true 
hyperprolactinemia [10, 18, 37].  
Although the majority of macroprolactinemia cases are asymptomatic, a number of patients 
experienced the main hyperprolactinemia-related symptoms due to the rise in the levels of 
monomeric PRL, that could not be differentiated from those with true hyperprolactinemia [7-11]. 
The association of the relatively common symptoms of galactorrhea and oligomenorrhea in patients 
with macroprolactinemia characterized by the simultaneous presence of excess serum 
macroprolactin and monomeric PRL concentrations may be explained as coincidental [10]. In 
addition the macroprolactin complex may intermittently dissociate in vivo in some cases, releasing 
monomeric PRL that causes the symptoms attributable to hyperprolactinemia [38]. Moreover, 
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macroprolactinemia may occur simultaneously with increased concentrations of free PRL plus other 
causes of hyperprolactinemia. A range of other causes, from physiological (pregnancy), to 
pharmacological and pathological  (including stress, hypothyroidism, renal and hepatic failure, 
intercostal nerve stimulation by trauma or surgery, and polycystic ovary disease) can contribute to a 
small rise in the levels of little PRL. The presence of increased levels of monomeric PRL is of 
primarly concern and therefore it is important in these symptomatic patients with 
macroprolactinemia to identify the exact pathologic state routinely and to introduce the adequate 
treatment with dopaminergic agonists. In cases of exclusion of all the causes and negative pituitary 
imaging idiopathic hyperprolactinemia should be established [39]. Moreover, it has recently been 
found that the coexistence of macroprolactinemia and the presence of raised free PRL 
concentrations in women with oligo-/amenorrhoea was associated with a higher risk of pituitary 
adenomas (36%). Therefore, pituitary magnetic resonance imaging should perhaps be mandatory in 
such cases [40]. However, hyperprolactinemia with high levels almost exclusively due to the 
presence of macroprolactin may occur in rare cases of invasive macroprolactinoma with preserved 
biological activity resulting in suppressed gonadotrophin levels and typical clinical presentation 
represents similarly to monomeric [12].  
6. Conclusion 
According to current concepts, macroprolactin is a biologically inactive, high molecular 
mass complex of PRL with IgG and its accumulation in serum has little, if any, pathological 
significance in patients with macroprolactinemia and normal concentrations of monomeric PRL. Its 
presence is suspected mainly in patients with mild hyperprolactinemia who are asymptomatic or 
with a low incidence of hyperprolactinemia-related symptoms and with negative pituitary imaging. 
Macroprolactinemia has been considered a benign clinical condition and thought to be a cause of 
apparent resistance to antiprolactinemic drugs. Therefore, no pharmacological treatment or other 
medical procedures and diagnostic investigations without prolonged follow-up may be required.   
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However, macroprolactinemia may also occur in patients with any of the conventional 
symptoms of hyperprolactinemia and radiological pituitary findings that could not be differentiated 
from those with true hyperprolactinemia. The symptoms of hyperprolactinemia are mostly 
attributed to the excess of monomeric PRL and therefore its presence is of overridden concern, and 
the diagnosis of macroprolactinemia in this setting is misleading and inappropriate. An excess of 
monomeric PRL with macroprolactinemia may be explained as coincidental or by intermittent 
dissociation of macroprolactin. In addition, a range of other causes, (physiological, pharmacological 
and pathological, including stress, pituitary adenomas, hypothyroidism, renal and hepatic failure, 
intercostal nerve stimulation, and polycystic ovary disease) can also contribute to the rise in the 
levels of monomeric PRL. It is important for patients with elevated monomeric PRL to undergo 
routine evaluation of hyperprolactinemia identifying the exact pathologic state and introducing 
adequate treatment regardless of the presence of macroprolactin. In addition,  macroprolactinemia 
of pituitary origin with clinical manifestations similar to patients with true hyperprolactinemia may 
rarely occur due to bioactive macroprolactin associated with pituitary adenomas. In these cases 
when excess of macroprolactin occurs with clinical manifestations of hyperprolactinemia, 
macroprolactinemia should be regarded as a pathological biochemical variant of 
hyperprolactinemia. An individualized approach to the management of such patients with 
macroprolactinemia may be necessary and pituitary imaging, dopamine treatment, and prolonged 
follow-up should be applied. However, in cases of exclusion of all the causes and negative pituitary 
imaging idiopathic hyperprolactinemia should be established. 
Therefore, it would be recommendable to make different professionals (such as 
endocrinologists, gynaecologists, pharmacologists and general practioners and all those involved in 
the management of hyperprolactinemia due to macroprolactin) aware of macroprolactinemia 
because of its frequent occurrence and timely recognition. In addition, for the accurate and early-
stage diagnosis of macroprolactinemia a close communication between the laboratory and the 
clinicians should be more frequently applied. Moreover, the importance of  routine screening of all 
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hyperprolactinemic sera for macroprolactin and a more meaningful clinical measurement of the 
bioactive monomeric PRL content with proper medical education and knowledge dissemination of 
the meaning of macroprolactinemia would be desirable.                                  
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